CCCC Stock Reverses Pre-Market Gains After Roche Tie-Up To Develop Cancer Treatments - Retail Sees Strong Upside

• C4 Therapeutics is also eligible to earn tiered royalties on future product sales.
• C4 and Roche will focus on developing emerging cancer treatments using degrader-antibody conjugates and targeted protein degradation processes.
• The companies will work together on two programs to develop the new cancer treatments. 

Shares of C4 Therapeutics, Inc. (CCCC) reversed pre-market gains to edge 2% lower on Thursday, after the company expanded its partnership with Swiss pharmaceutical company Roche to develop cancer treatments.

C4 Therapeutics said the new collaboration will focus on developing emerging cancer treatments using a degrader-antibody conjugate (DAC) and targeted protein degradation (TPD) processes. 

“Our new collaboration leverages C4T’s ability to design highly catalytic and selective degraders, as well as degrader payloads for DACs, alongside Roche’s extensive experience developing ADCs with specific binding. Together, these capabilities build a powerful new modality that can offer transformative medicines for patients,” said Andrew Hirsch, President and CEO of C4 Therapeutics.

C4 Could Earn Up To $1 Billion

The companies will work together on two programs to develop new cancer treatments. C4 Therapeutics will design the drug components using its TORPEDO platform, which uses advanced tools and AI to target harmful proteins.  

Roche will create the antibodies and combine them with the drug. Roche will also handle testing, development, and sales. 

C4 Therapeutics will receive a $20 million upfront payment for the two programs, with the potential for additional payments if Roche opts to include a third target. The agreement also includes near-term discovery milestones, while total milestone payments could exceed $1 billion. Additionally, the firm is eligible to earn tiered royalties on future product sales.

How Did Retail Traders React?

Despite the reversal after the opening bell, retail sentiment on Stocktwits for CCCC flipped to ‘extremely bullish’ from  ‘bearish’ a day earlier, amid ‘high’ message volumes.

One user said that, based on the contract, the stock should be around $4 to $5. It is currently around $2.8.

Another bullish user highlighted the company’s runway until 2028.

The stock has shot up more than 35% so far this year.

For updates and corrections, email newsroom[at]stocktwits[dot]com.